Saudi Pharmaceutical Industries & Medical Appliances Corp. 2070

TADAWUL · Saudi Arabia · Health Technology

SAR 30.90-0.08 (-0.26%)

Market closed· Oct 1, 2026, 12:15 PM UTC· SAR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Saudi Pharmaceutical Industries & Medical Appliances Corp. 2070

TADAWUL · Saudi Arabia · Health Technology

SAR 30.90-0.08 (-0.26%)

Market closed· Oct 1, 2026, 12:15 PM UTC· SAR · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-1.28% · 6MFull-screen chart

Open SAR 30.82High SAR 31.26Low SAR 30.60Close SAR 30.90Volume 219.24K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SAR 30.98
Day range: SAR 30.60 – SAR 31.26
52-week range: SAR 24.96 – SAR 33.32
Volume: 219.24K
Market cap: SAR 3.72B
P/E (TTM): 17.3
Dividend yield (annualized): 1.13%
Next earnings date: 2026-11-03
Avg. volume (1Y): 499.07K

Performance

1 week

-4.92%

1 month

-0.13%

3 months

+7.37%

6 months

-0.75%

Year to date

+19.58%

1 year

+6.77%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Saudi Arabia
Exchange: TADAWUL
Shares outstanding: 119.36M
ISIN: SA0007879188
Beta: 1.08

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJun 23, 2026

Genetix Biotherapeutics and SPIMACO Announce Strategic Agreement to Commercialize and Manufacture LYFGENIA™ & ZYNTEGLO™ in Saudi Arabia and the Broader Middle East Region

SOMERVILLE, Mass., June 23, 2026--Genetix Biotherapeutics Inc. and the Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its wholly owned subsidiary, SPIMACO Bio, today announced an exclusive collaboration and license agreement for the development, commercialization, and localized manufacturing of LYFGENIA™ and ZYNTEGLO™ in Saudi Arabia and across the broader Middle East. LYFGENIA and ZYNTEGLO are first-in-class, one-time gene addition cell therapies for the treatm

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.